Technologies

AIDD is an integrated tool and a radically new way to discovery new drugs for neurodegenerative diseases (Alzheimer’s, Epilepsy, Ageing, etc.).

Nowadays, to properly design and develop advanced materials capable to preserve for long times their performance under aggressive environments such as power generation plants, renewables, nuclear reactors and electronics of new generation, transport on ground and on space, aeronautics, catalysis, biomedical implants, the optimization of metallurgical processes involved is crucial.

22q11.2DS(DGS) deletion syndrome is a rare and phenotypically variable multiorgan syndrome, currently without any cure. Our aim is to develop a standardized approach to formulate pharmacological products useful for clinical trials direct to prevent some serious clinical manifestations of adolescence and adulthood, such as neuropsychiatric and musculoskeletal diseases, or to eliminate or improve cardiovascular defects during embryonic development.

Mirrors for space applications, besides featuring suitable optical properties, should be light, resistant to mechanical stresses, and unsensitive to light-shadow thermal cycling. The standard optical materials easily fulfill optical and thermal requirements, but are fragile, and the mirrors must be thick (typically 1/6 of the diameter). For this reason they are heavy, and the only available solution is to lighten them, by removing material from the back side, still preserving the necessary mechanical robustness and optical quality.

The object of the technology is the development of a transferable methodology from the laboratory scale to the pilot scale to be validated in the industrial setting for the treatment of basic waste of natural polymers of agro-food or manufacturing industry.

Therapeutic strategies targeting cell cycle in cancer have in general failed in the clinic since the drugs have lacked the therapeutic index required to achieve a robust response against cancer cells with little or no cytotoxic effect on normal cells. NEK6 kinase, which is implicated in cell cycle control, has recently emerged as an attractive target for the development of novel anticancer drugs with enhanced therapeutic index.

With the advent of senolytic agents, capable of selectively removing senescent cells in “aged” tissues, the perception of age-associated diseases has changed from being an inevitable to a preventable phenomenon of human life. The present invention is part of this research topic with the identification of molecules with potential pro-apoptotic activity, specifically with senolytic activity. The computational approach adopted, is based on combining ligand-base and structure-based virtual screening.

Design and testing of neoproteins with optimized nutritional value, according to needs, avoiding their degradation - thus maintaining a high production yield - and aggregation (which could make them indigestible). Neoproteins are produced and characterized in plant systems as bioreactors. We have already created zeolin, formed by the fusion of a bean seed protein with a portion of a maize seed protein.

The systems simulate, with high reproducibility, the conditions that occur in the different compartments of the gastrointestinal tracts and are promising to accurately mimic the digestive process, with the possibility to evaluate bioaccessibility and bioavailability. Moreover, the systems permit to study the synergic and reciprocal effects between the bioactive compounds characteristic of food and intestinal microbiota.

Plants can compete favorably with traditional expression systems (mammalian cells, yeasts or bacteria) to produce recombinant proteins/peptides of pharmaceutical/industrial/agrifood interest. This technology names “Plant Molecular Farming”. The CNR-IBBA research team offers the study of new strategies for the expression and optimization of recombinant proteins/peptides in plant-based systems (plant tissues, transgenic plants, plant cell culture). Our pipeline is based on the following modules:

The proposed technology deals with the development of active SERS (Surface Enhanced Raman Scattering) substrates ad hoc designed for diagnostics of cultural heritage. The substrates are prepared starting from common commercial 'polishing film' sheets (lapping optical fibers) showing an intrinsic roughness (48- 1000 nm) that favors the SERS effect. A pattern of silver or gold nanoparticles are deposited on these films through Pulsed Laser Deposition (PLD).

We developed an hybrid organic-inorganic composite consisting of a 2D perovskite and a copolymer. At room temperature the composite is highly transparent in the visible region with transmittance > 90%. At higher temperatures, the movement of the polymer chains releases the precursors, allowing the perovskite formation, which results in a colored film. The color changes according to the ‘n’ value of the PVK. PVK with n=1 starts coloring at 70°C, achieving a ∆T_max = 91.5% at 510 nm.

The invention is a synthetic method to prepare colloidal nanomaterials of V-VI-VII semiconductors that do not contain toxic elements. This is the first method for the synthesis of mixed anion nanomaterials without toxic elements at large, which permitted to obtain, among others, bismuth chalcohalide nanocrystals that are arguably considered as one of main candidates to be the next big thing for light energy conversion.

Recently, it has been demonstrated that Raman spectroscopy can play a fundamental role in assisting the work of the anatomopathologist by allowing classification of oncological samples with practically 100% accuracy in oncological diagnosis.

This is a high-throughput sequencing based method to map euchromatin and heterochromatin accessibility. The method is based on the sequential extraction of distinct nuclear fractions containing: soluble proteins (S1 fraction); the surnatant obtained after DNase treatment (S2 fraction); DNase-resistant chromatin extracted with high salt buffer (S3 fraction); and the most condensed and insoluble portion of chromatin, extracted with urea buffer that solubilizes the remaining proteins and membranes (S4 fraction).